Seven to nine hours a night is the scientific recommendation—but is this number universal, or is it possible that women need ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

A 2020 analysis found that adults who slept fewer than 7 hours per night had a 41% increased risk of developing obesity. Meanwhile, sleeping longer didn’t increase the risk. The effect of sleep ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Irregular sleep patterns, common among young adults aged 25-40, raise the risk of heart diseases due to disrupted sleep-wake ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the ...